Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

20 for 2020 – Five pharma companies to watch

20 for 2020 – Five pharma companies to watch

treatment pathway in HER2-positive breast cancer as quickly as possible, challenging Roche’s duo of Herceptin and Perjeta (pertuzumab).

Seattle Genetics wins FDA priority review for oral HER2 drug

Seattle Genetics wins FDA priority review for oral HER2 drug Herceptin plus Xeloda is a standard treatment regimen for HER2-positive breast cancer, in patients previously treated with Herceptin and Roche’s other HER-2 targeting drugs Perjeta (pertuzumab) and Kadcyla

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Roche posts minor sales miss in Q4 as biosimilar pressure grows Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely  Perjeta (pertuzumab) for HER2-positive breast cancer,   Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy  Hemlibra (emicizumab) and

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine). ... This first regulatory approval is based on the DESTINY-Breast01 trial in patients who had previously been treated with Herceptin, Perjeta or Kadcyla.

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla HER2 antibodies, lagging behind Herceptin and Perjeta (pertuzumab).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics